Olpasiran and pelacarsen could be cost-effective at AU$1867 and AU$984 per year for secondary prevention of coronary heart disease, an early Australian health technology assessment (J Clin Lipidol 2024)

Original title: Early health technology assessment of gene silencing therapies for lowering lipoprotein(a) in the secondary prevention of coronary heart disease

J Clin Lipidol · 1 January 2024 · 6

Burvill A, Watts GF, Norman R, Ademi Z

Using a decision-tree and lifetime Markov model informed by the OCEAN(a) Outcomes (olpasiran, Lp(a) 260 nmol/L at baseline) and Lp(a)HORIZON (pelacarsen, Lp(a) 226 nmol/L at baseline) trial populations and Mendelian randomisation estimates of clinical benefit, this Australian early health technology assessment modelled cost-effectiveness of the two gene-silencing therapies added to standard of care for recurrent coronary heart disease. Olpasiran added 0.87 discounted quality-adjusted life years per person and would be cost-effective at an annual price of AU$1867 (AU$467 per dose) at a threshold of AU$28,000 per QALY; pelacarsen would be cost-effective at AU$984 per year (AU$82 per dose). At a threshold of AU$50,000 per QALY, cost-effective prices rise to AU$4207 for olpasiran and AU$2464 for pelacarsen.

Original abstract

Background: Olpasiran and pelacarsen are gene-silencing therapies that lower lipoprotein(a). Cardiovascular outcome trials are ongoing. Mendelian randomization studies estimated clinical benefits from lipoprotein(a) lowering.

Objective: Our study estimated prices at which olpasiran and pelacarsen, in addition to standard-of-care, would be deemed cost-effective in reducing risk of recurrent coronary heart disease (CHD) events in the Australian healthcare system.

Methods: We developed a decision tree and lifetime Markov model. For olpasiran, participants had CHD and lipoprotein(a) 260 nmol/L at baseline and three-monthly injections, profiled on OCEAN(a) Outcomes trial (NCT05581303). Baseline risks of CHD, costs and utilities were obtained from published sources. Clinical trial data were used to derive reductions in lipoprotein(a) from treatment. Mendelian randomization study data were used to estimate downstream clinical benefits. Annual discounting was 5%. For pelacarsen, participants had CHD and lipoprotein(a) 226 nmol/L at baseline and one-monthly injections, profiled on Lp(a) HORIZON (NCT04023552) trial.

Results: Olpasiran in addition to standard-of-care saved 0.87 discounted quality-adjusted life years (QALYs) per person. Olpasiran in addition to standard-of-care would be cost-effective at annual prices of AU$1867 (AU$467 per dose) at threshold AU$28,000 per QALY. Pelacarsen would be cost-effective at annual prices of AU$984 (AU$82 per dose). For incremental cost-effectiveness ratio (ICER) threshold AU$50,000 per QALY, olpasiran and pelacarsen would be cost-effective at annual prices AU$4207 and AU$2464, respectively.

Conclusion: This early health technology assessment model used inclusion criteria from clinical trials. Olpasiran and pelacarsen would be cost-effective if annual treatment prices were AU$1867 and AU$984, respectively, from the Australian healthcare perspective.

Summary written by lp-a.org from the published abstract; figures as published. Page updated 18 August 2026. Methods.